| mTOR抑制剂治疗肾细胞癌的研究进展 |
| |
| 引用本文： | 刘旭,张东亮,刘文虎. mTOR抑制剂治疗肾细胞癌的研究进展[J]. 中国全科医学, 2011, 14(3) |
| |
| 作者姓名： | 刘旭 张东亮 刘文虎 |
| |
| 作者单位： | 首都医科大学附属北京友谊医院肾内科,首都医科大学肾病学系,北京市,100050 |
| |
| 摘 要： | 哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是一种丝/苏氨酸蛋白激酶,在肾细胞癌(renal cell carcinoma,RCC)的发生、发展过程中起着重要作用。mTOR抑制剂能够抑制mTOR相关信号通路异常引起的癌基因的转化、肿瘤的生长以及肿瘤血管的生成。Temsirolimus和依维莫司(everolimus)被批准应用于临床,为进展期RCC的治疗和预后带来新的曙光。
|
| 关 键 词： | 肾细胞癌 mTOR抑制剂 治疗 进展 |
Research Progress of mTOR Inhibitors in the Treatment of Renal Cell Carcinoma |
| |
| LIU Xu,ZHANG Dong-liang,LIU Wen-hu. Research Progress of mTOR Inhibitors in the Treatment of Renal Cell Carcinoma[J]. Chinese General Practice, 2011, 14(3) |
| |
| Authors: | LIU Xu ZHANG Dong-liang LIU Wen-hu |
| |
| Affiliation: | LIU Xu,ZHANG Dong-liang,LIU Wen-hu.Department of Nephrology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China |
| |
| Abstract: | Mammalian target of rapamycin(mTOR) is a serine / threonine protein kinase,and it plays an important role in the occurrence and development of renal cell carcinoma(RCC).mTOR inhibitors can inhibit cancer gene transformation caused by abnormal mTOR signaling pathway,tumor growth and tumor angiogenesis.Temsirolimus and everolimus are approved in clinical application,and bring new hope for the prognosis of advanced renal cell carcinoma. |
| |
| Keywords: | Renal cell carcinoma mTOR inhibitor Therapy Progress |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
